Unternehmensübersicht
Biogen Inc. operates as a premier entity within the healthcare sector, specifically functioning as a general drug manufacturer dedicated to the discovery, development, and delivery of advanced therapies across the United States, Europe, Germany, Asia, and international markets. The firm focuses on providing critical treatments for severe neurological conditions, including multiple sclerosis with products like TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI, as well as SPINRAZA for spinal muscular atrophy and SKYCLARYS for Friedreich's ataxia. As a significant player in the pharmaceutical industry, the company manages a substantial operational footprint employing approximately 7,500 personnel globally. With a market capitalization of $26.98 billion and annual revenue reaching $9.89 billion, Biogen demonstrates a scale that positions it as a major force in the biotechnology landscape, reflecting a high valuation relative to its revenue base which indicates strong market confidence and substantial resource allocation for research and development.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $9.89 billion, generating net income of $1.29 billion and an EBITDA of $3.60 billion, illustrating a robust operational cash generation capability before interest and tax obligations. The substantial gap between the $9.89 billion revenue and the $1.29 billion net income reveals a significant cost structure where operating expenses, including research, development, and sales costs, consume a considerable portion of gross earnings before arriving at the bottom line. Despite the large revenue figure, the net income represents a specific profit margin of 13.1%, indicating the efficiency with which the company converts sales into actual profit after all expenses. The firm generates free cash flow of $1.98 billion, a metric that signifies strong financial flexibility allowing for potential strategic investments, debt repayment, or share repurchases without compromising core operations. Profitability is further supported by a gross margin of 78.9%, an operating margin of 19.6%, and a profit margin of 13.1%, where the high gross margin suggests strong pricing power or low cost of goods sold, while the lower operating and profit margins reflect the heavy investment in R&D and commercialization typical of the pharmaceutical sector. On the balance sheet, the company holds $3.82 billion in cash against total debt of $6.66 billion, resulting in a debt-to-equity ratio of 36.47%, which indicates a leveraged balance sheet where debt levels are significant relative to equity but must be managed carefully against interest rates. Liquidity is well-positioned with a current ratio of 2.68, meaning the company possesses more than two and a half times the current assets needed to cover its current liabilities, ensuring short-term solvency. Management effectiveness is measured by a return on equity of 7.4% and a return on assets of 6.1%, figures that show the company generates modest but positive returns on its shareholders' capital and total asset base, respectively.
Bewertungsanalyse
Biogen's valuation is characterized by a trailing P/E ratio of 20.91 and a forward P/E of 11.33, where the significant difference between these two metrics implies that the market expects earnings growth to accelerate substantially in the coming years to meet the lower forward multiple. The price-to-book ratio stands at 1.48, indicating that the market values the company's equity at approximately 48% above its book value, which often reflects intangible assets like intellectual property and brand value not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.73 and an EV/EBITDA of 8.28 provide additional context, suggesting the stock is priced reasonably relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the stock has a 52-week high of $202.41 and a 52-week low of $110.04, and based on the provided data points, the current market capitalization of $26.98 billion implies a share price position that must be contextualized within this wide trading range to understand the equity value distribution. The beta coefficient of 0.14 is notably low compared to the broader market, indicating that the stock exhibits minimal price volatility and tends to move independently of general market fluctuations, offering a distinct risk profile for a diversified portfolio.
Growth & Income
The company's financial trajectory shows a year-over-year revenue growth of -7.1%, while earnings growth is marked as N/A due to the specific financial reporting data available, suggesting a period of revenue contraction that impacts the overall top-line expansion. In the absence of earnings growth data to confirm a divergence, the revenue decline indicates a challenging market environment or product lifecycle issues that the company must navigate. Biogen does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company chooses to reinvest its net income of $1.29 billion and free cash flow of $1.98 billion directly back into research, development, and operational growth rather than returning capital via cash payouts. This reinvestment strategy is typical for pharmaceutical firms prioritizing pipeline expansion over immediate shareholder income. Overall, the growth and income profile for Biogen Inc. is currently defined by a focus on capital preservation and strategic reinvestment during a period of revenue contraction, with no reliance on dividend income for investors.